Joseph G. Reynolds - Concepedia

Author

Joseph G. Reynolds

Merrimack Pharmaceuticals (United States)

Also Known As

Joseph G. Reynolds, Joseph Reynolds, Reynolds, Joseph

Publications

606

Citations

H-Index

Concepts

All Affiliations

Merrimack Pharmaceuticals (United States)Indiana University – Purdue University Indianapolis Acceleron Pharma (United States)Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Joseph G. Reynolds is an author at Merrimack Pharmaceuticals (United States) specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	206
2	Cell Biology	2	2	94
3	Immunology	2	2	94
4	Engineering	1	1	65
5	Pathology	1	1	29

Joseph G. Reynolds

Publications

588

Citations

H-Index

Page 1

	Year	Citations
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer Kathy D. Miller, Javier Cortés, Sara A. Hurvitz, BMC Cancer	2016	153
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study Pamela N. Münster, Ian E. Krop, Patricia LoRusso, British Journal of Cancer	2018	117
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks, Toxicology and Applied Pharmacology Tumor BiologyOncologyAnti-tumorigenic EffectsMedicineTumor Targeting	2012	112
A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti, Blood	2019	66
Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect Bart S. Hendriks, Stephan G. Klinz, Joseph G. Reynolds, Molecular Cancer Therapeutics NanoparticlesNanotherapeuticsEngineeringImmunologyImmunotherapeutics	2013	65
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study Uwe Platzbecker, Katharina S. Götze, Philipp Kiewe, Journal of Clinical Oncology	2022	34
Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer Patricia LoRusso, Ian E. Krop, Kathy D. Miller, Cancer Research Breast OncologyAbstract Ct234MedicineImmunologyPharmacology	2015	29
Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, The Journal of Clinical Pharmacology	2020	12

Page 1